Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2505MR)

This product GTTS-WQ2505MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2505MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2283MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ8703MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ14308MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ5734MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ331MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ10530MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ11921MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW